Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
Allergol. immunopatol
; 50(6): 47-52, 01 nov. 2022. tab
Article
en En
| IBECS
| ID: ibc-211523
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT (AU)
Palabras clave
Texto completo:
1
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Asma
/
Alérgenos
/
Desensibilización Inmunológica
/
Antiasmáticos
/
Antialérgicos
/
Rinitis Alérgica
/
Omalizumab
Límite:
Humans
Idioma:
En
Revista:
Allergol. immunopatol
Año:
2022
Tipo del documento:
Article